• Earlier this week, Regeneron Pharmaceuticals announced that the FDA approved Pasatru (garetosmab-grts), a monthly intravenous monoclonal antibody, to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with the ultra-rare disease fibrodysplasia ossificans progressiva.
• The approval is based on Phase 3 OPTIMA trial data showing Pasatru cut new abnormal bone lesions to just a few cases compared with many more on placebo, while also enabling administration across settings including home infusion.
• Now we’ll examine how this first-in-class FOP treatment, built on Regeneron’s VelocImmune platform, may reshape its broader investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Regeneron Pharmaceuticals Investment Narrative Recap

To own Regeneron, you need to believe its core franchises can withstand pricing and biosimilar pressure while new medicines gradually diversify revenue. The Pasatru approval meaningfully reinforces that diversification story in a niche area, but it does not change that the key near term catalyst remains EYLEA HD execution and pricing, nor that the biggest risk is concentrated exposure to EYLEA and Dupixent in the face of payer and competitive headwinds.

Among recent announcements, the FDA’s decision in April to extend EYLEA HD dosing intervals up to 20 weeks for some patients is most relevant. Together with Pasatru, it illustrates the tension between Regeneron’s efforts to deepen existing franchises and expand into new biologics, and the ongoing risk that branded anti VEGF share and pricing pressure could still weigh on overall revenue progress.

Yet beneath the promise of new FOP treatments, there is also the underappreciated risk that concentrated exposure to EYLEA and Dupixent could still...

Regeneron Pharmaceuticals' narrative projects $19.4 billion revenue and $6.0 billion earnings by 2029.

Uncover how Regeneron Pharmaceuticals' forecasts yield a $833.31 fair value, in line with its current price.

Exploring Other Perspectives

While consensus focuses on EYLEA risk, the more optimistic analysts lean on Dupixent’s potential, projecting about US$21.0 billion revenue and US$7.7 billion earnings by 2029, so Pasatru may eventually shift how you weigh these very different stories.

Explore 6 other fair value estimates on Regeneron Pharmaceuticals - why the stock might be worth 12% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Regeneron Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Regeneron Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Regeneron Pharmaceuticals' overall financial health at a glance.

Curious About Other Options?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• Find 48 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.